Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old

PHASE3CompletedINTERVENTIONAL
Enrollment

1,893

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

July 31, 2007

Study Completion Date

December 31, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza virus vaccine

Two intramuscular injections of the investigational influenza virus vaccine administered 4 weeks part to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.

BIOLOGICAL

Comparator influenza vaccine

Two intramuscular injections were administered 4 weeks apart to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.

Trial Locations (2)

Unknown

Site 2: C1425AWK, Buenos Aires

Site 1: X5000BJH, Córdoba

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Vaccines

INDUSTRY

lead

Novartis

INDUSTRY